Femasys (NASDAQ:FEMY) Given New $10.00 Price Target at Chardan Capital

Femasys (NASDAQ:FEMY) had its price target lowered by Chardan Capital from $12.00 to $10.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright cut their price target on Femasys from $13.00 to $12.00 and set a buy rating for the company in a report on Friday, August 9th.

Femasys Stock Performance

Shares of NASDAQ FEMY traded up $0.03 during midday trading on Wednesday, hitting $1.09. 26,434 shares of the company’s stock traded hands, compared to its average volume of 404,334. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.02 and a current ratio of 8.43. The stock has a market capitalization of $24.30 million, a price-to-earnings ratio of -1.26 and a beta of -2.81. The firm has a fifty day moving average of $1.09 and a 200 day moving average of $1.30. Femasys has a 1 year low of $0.25 and a 1 year high of $4.75.

Femasys (NASDAQ:FEMY) last announced its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.50 million. Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. On average, analysts forecast that Femasys will post -0.72 earnings per share for the current year.

Institutional Trading of Femasys

A hedge fund recently raised its stake in Femasys stock. CM Management LLC increased its position in Femasys Inc. (NASDAQ:FEMY) by 6.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the period. CM Management LLC owned about 1.91% of Femasys worth $484,000 at the end of the most recent quarter. 65.27% of the stock is currently owned by institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.